查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832142

动物抗菌肽市场（按产品类型、应用和最终用户）—2025-2032 年全球预测

Animal Antibacterial Peptide Market by Product Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，兽用抗菌肽市场将成长至 146.8 亿美元，复合年增长率为 17.40%。

主要市场统计数据
基准年2024年 40.6亿美元
预计2025年 47.7亿美元
预测年份：2032年 146.8亿美元
复合年增长率（%） 17.40%

兽用抗菌肽的策略方向，包括科学进步、监管变化、相关人员奖励以及商业化的实际采用途径

随着相关人员对日益增长的抗生素抗药性和不断变化的监管预期做出反应，兽用抗菌肽领域已进入科学和商业性利益日益增长的时期。基于胜肽的抗菌策略利用多种生物机制，具有特异性，可减少抗药性细菌的产生，并与综合动物健康计划相容。胜肽合成、製剂和标靶递送技术的发展已将许多概念从学术概念验证推进到转化开发阶段，促使更广泛的商业相关人员将胜肽评估为传统抗生素的可行替代品或补充品。因此，兽医、饲料配方师、水产养殖生产商和生物技术公司正在重新评估其治疗通讯协定、牛健康经济学和产品定位，并更清楚地了解胜肽解决方案独特的风险回报状况。

从实验室创新到商业性化的转变需要克服科学检验、生产复杂性和监管协调等诸多挑战。强大的分析方法和可扩展的合成平台的引入降低了技术壁垒，而佐剂和递送技术的进步则提高了体内疗效和稳定性。这些趋势的融合为那些能够整合多学科能力、与监管机构及早沟通并制定可操作证据生成策略的组织打开了机会之窗。展望未来，成功将取决于能否将机制效益转化为可证明的动物健康成果、营运相关性以及能够引起不同最终用户共鸣的商业性价值提案。

透过合成突破、诊断整合和不断发展的监管接受度，探索影响兽用抗菌肽发展的关键转变

在技​​术、监管和市场催化剂的推动下，兽用抗菌肽领域正在经历变革，这些因素正在重新定义竞争动态。在技​​术方面，合成创新和纯化製程的改进显着减少了关键的技术瓶颈，使製造商能够生产出保真度更高、理化性质更精准的胜肽。同时，精准诊断和病原体监测正在推动更有针对性的治疗和预防干预措施，增强了那些具有窄频谱和物种特异性活性并最大程度减少微生物组破坏的产品的商业性价值。

监管态度也在不断演变。只要提交严格的安全性和有效性数据，监管机构对能够清楚证明动物福利或环境效益的替代抗菌药物的接受度日益提高。这种监管势头正激励製造商推行系统性的证据生成项目，并将田间试验和疗效比较终点纳入其中。同时，饲料製造商和水产养殖户等终端用户正在寻求能够与现有生产系统无缝整合的解决方案，这催生了对在饲料基质和水中稳定且剂量可预测的配方的需求。这种累积的转变有利于那些采用系统化方法的组织，该方法能够协调研发、製造和商业化，从而减少产品属性与营运现实之间的摩擦。

重点评估2025年美国累积关税措施将如何影响胜肽原料采购、契约製造决策与供应链弹性策略

2025年美国关税措施加强了参与兽用抗菌肽开发和商业化的机构对供应链的考量。由于胜肽生产通常依赖专门的原料、试剂和外包合成能力，关税政策的变化将影响筹资策略以及全球製造与国内製造的相对竞争力。先前依赖低成本国际供应商的公司正在重新评估总到岸成本、前置作业时间和库存政策，以降低关税波动带来的风险。随着这些策略调整的实施，一些公司正在探索近岸外包或建立冗余供应商网络，以保持生产连续性并加快对需求波动的反应。

在营运层面，与关税相关的成本压力可能会影响垂直整合、契约製造伙伴关係关係以及分析测试和最终配方等高价值活动选址的决策。拥有灵活供应链的公司能够调整采购、认证替代试剂并调整批次调度，从而更好地应对关税带来的干扰，同时又不影响开发和商业化时间表。此外，对采购弹性的日益关注正在推动对供应商资质资格确认、策略性库存缓衝和合约保障措施的投资，从而降低价格衝击的风险。总而言之，到2025年，关税变化的累积影响凸显了积极主动地重新设计供应链、进行情境规划以及更谨慎地协调製造策略和商业性节奏的必要性。

全面的细分洞察将产品类型、应用和最终用户组合与证据需求、配方需求和市场途径选择联繫起来

了解细分市场对于设计符合客户需求和技术可行性的产品系列和商业化路径至关重要。从产品类型的角度来看，天然胜肽和合成胜肽之间存在着一个关键区别，而合成胜肽又根据炼长进一步细分为长链、中炼和短链，这些类别的稳定性、效力和生产影响各不相同。这些产品层面的属性会影响配方选择、给药途径和成本结构，并指南企业应将製程开发和分析表征工作的重点放在何处。

不同的使用情况显示出不同的证据要求和采用曲线。预防性用途，包括疾病预防策略和疫苗佐剂，需要强大的安全性，并在群体免疫或降低疾病发生率方面具有明显的益处。治疗性用途分为感染疾病治疗和皮肤病治疗，每种用途都需要受控的临床评估和给药策略，以应对动物种类、年龄和健康状况的差异。使用要求和产品特性之间的相互作用将决定临床试验的设计、监管途径的选择以及可申请的权利要求的性质。

最终用户细分凸显了水产养殖场、饲料製造商、研究机构和兽医诊所之间在营运和商业化方面的差异。饲料製造商必须客製化水产饲料和牲畜饲料的兼容性，并强调加工稳定性和剂量均匀性。同时，研究机构（包括学术机构和生物技术公司）推动早期发现、机制阐明和转化研究。兽医诊所区分大型和小型动物诊所的需求，这会影响剂型、给药途径和从业人员训练需求。这些横断面细分维度清楚地表明，产品开发和商业化不可能千篇一律。相反，需要根据每个细分领域的技术限制和决策驱动因素量身定制证据包、配方策略和上市模式。

美洲、欧洲、中东和非洲以及亚太地区的商业化和监管观点将推动不同的采用路径和战略重点

在兽用抗菌肽领域，监管策略、商业化时机和投资重点因地区而异。在美洲，监管机构和相关人员优先考虑抗菌药物的管理和显着减少抗生素依赖，从而创造出动物健康结果和经济合理性影响采购决策的环境。该地区拥有跨国动物用药品公司，并建立了成熟的製造外包网络，这使得透过监管和临床阈值的候选药物能够快速扩大规模，但也加剧了争夺兽医和生产商注意力的竞争。

欧洲、中东和非洲的法律规范往往不尽相同，欧洲司法管辖区通常对安全性和环境影响设定更高的标准，而该地区其他国家可能优先考虑可及性和可负担性。在这些地区营运的製造商必须协调不同的核准途径和预期数据，预测最严格的监管要求，同时设计适合当地商业条件的证据产生策略。水产养殖和集约化畜牧生产的快速增长对传统抗生素的替代品产生了巨大的需求，一些市场的监管现代化为新疗法铺平了道路。然而，亚太地区也强调成本竞争力和供应链接接近性，迫使公司优先考虑定价策略和当地製造伙伴关係。任何地区的成功都依赖于将科学检验与尊重当地监管细微差别和客户经济的务实商业化方法相结合。

竞争和企业创新情报，展示现有企业、生物技术创新者和製造专家如何合作推进胜肽候选物并为商业化做好准备

动物用药品公司、新兴的生物技术公司、专业的肽类研发公司和受託製造组成。现有的动物用药品公司在监管事务、分销网络和客户关係方面拥有优势，并且能够在有证据支持其临床和经济价值的情况下，将胜肽产品纳入其现有产品组合。规模较小的生物技术公司和大学衍生公司经常推动早期创新，推动新的序列、交付平台和作用机制洞察，从而颠覆传统方法。

策略伙伴关係和授权安排是填补能力差距和加速商业化的常用机制。大型公司可能会与多肽专家达成研究合作或共同开发契约，以获得专有化学和可扩展的合成方法，而合约开发和生产组织在将候选化合物从实验室转移到符合GMP标准的生产过程中发挥关键作用。投资者和企业开发团队越来越关注那些在多肽序列和製剂方面展示清晰的转化途径、可重复的生产流程以及可防御的智慧财产权的公司。竞争优势通常取决于强有力的临床证据、稳健的生产能力以及提供适合现有动物用药品工作流程的实用剂型的能力。

向产业领导者提供可行的策略建议，以加速证据产生、确保供应链的弹性、儘早与监管机构接触并设计以最终用户为中心的商业化策略

产业领导者应实施一系列优先行动，加速负责任的采用，并在管理技术和商业性风险的同时，抢占先发优势。这种双重方法既在理想条件下有效，又在实际运作中体现出实际效益。其次，透过制定模组化製造策略，将关键品质属性的内部能力与提供规模化和冗余能力的合约合作伙伴结合，从而降低供应风险和与关税相关的中断。

第三，在开发早期就制定监管参与计划，使研究设计与预期的严格要求保持一致，并加快跨多个司法管辖区的核准。第四，设计产品形式和分销模式，透过强调饲料相容配方、易于管理的输送系统以及对从业人员的清晰指导，最大限度地减少对最终用户现有工作流程的干扰。第五，寻求将专有胜肽技术与分销管道和配方专业知识相结合的策略联盟，以实现更快的市场准入和更广泛的应用。实施这些建议需要跨职能管治、严格的产品组合优先排序，以及试行能够反映个别最终使用者细微需求的创新商业模式的意愿。

透明的调查方法结合了结构化的相关人员访谈、技术文献综述、监管分析和跨源检验，确保得出可靠且可行的结论

本分析整合了一级和二级研究、技术文献综述和相关人员参与，旨在形成基于证据的兽用抗菌肽观点。一级研究包括对兽医、饲料配方师、契约製造製造商和研究科学家的结构化访谈，旨在将技术主张转化为实际操作，并揭示该领域应用面临的障碍。二级资讯涵盖同行评审文献、监管指导文件和专利申请，旨在揭示技术发展轨迹和智慧财产权主题。

此分析方法将访谈资料的定性主题分析与跨司法管辖区法规结构的比较评估相结合，以突出不同市场对证据预期的差异。检验是透过跨资料来源的三角测量以及与专家的后续咨询来实现的，以检验假设并完善解释。此方法强调假设的透明度、对实证结果的保守解释，以及对既定事实和新兴假设的明确区分。结论尽可能反映基于可复製方法和支持性技术文献的共识观点，确保建议切实可行并与当前的科学和监管现实一致。

总结结论，整合技术前景、商业现实和策略路径，以指南兽用抗菌肽的采用和投资决策

综上所述，兽用抗菌肽是减少对传统抗生素依赖、改善动物健康和生产永续性的更广泛策略中一个前景广阔且实用的组成部分。胜肽设计和递送方面的科学进步，加上监管机构对替代品的开放态度，正在提升胜肽类干预措施的潜力。然而，成功的商业化取决于安全性和有效性的严格证据、生产的扩充性以及适应不同最终用户的现有营运模式的能力。整合跨职能能力、寻求策略伙伴关係关係并采用有计划的供应链和监管策略的组织可能最有能力将科学潜力转化为商业性影响力。

展望未来，胜肽的广泛应用之路可能是一个循序渐进且主导。早期的成功可能集中在肽比其他替代品具有明显优势的利基领域，例如局部的预防应用以及局部给药限制全身暴露的皮肤病治疗。经济高效的生产和可靠的临床数据的累积可能推动胜肽的更广泛应用。对于那些在科学严谨性和切合实际的商业化计画之间取得平衡的相关人员来说，胜肽提供了一种可靠的途径，既能实现管理目标，又能保持生产力和动物福利。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 越来越多地采用富含抗菌肽衍生物的植物来源饲料补充剂来提高牲畜免疫力
  • 针对家禽生产系统中特定通用感染疾病菌株的人工抗菌肽的开发
  • 胜肽递送技术的进展，例如用于在反刍动物胃肠道中定向释放的奈米胶囊技术
  • 北美和欧洲的监管激励措施正在推动对非抗生素生长促进剂的研究投资，以改善猪隻的健康
  • 新兴的噬菌体胜肽混合治疗方法可用于对抗养殖鱼类抗生素抗药性感染疾病
  • 生技新创公司与动物用药品公司建立Start-Ups伙伴关係，加速新型胜肽疗法的商业化
  • 整合人工智慧驱动的胜肽设计平台可优化抗菌功效并缩短动物保健领域的开发时间

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：动物抗菌胜肽市场（依产品类型）

  • 天然胜肽
  • 合成胜肽
    • 长链
    • 中型链条
    • 短链

第九章动物抗菌肽市场应用

  • 促进生长
  • 预防
    • 疾病预防
    • 疫苗佐剂
  • 治疗
    • 感染疾病治疗
    • 皮肤病治疗

第 10 章动物抗菌肽市场（按最终用户）

  • 水产养殖场
  • 饲料生产商
    • 水产饲料
    • 牲畜饲料
  • 研究所
    • 学术机构
    • 生技公司
  • 兽医诊所
    • 大型动物治疗
    • 小动物治疗

第 11 章：动物抗菌胜肽市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章动物抗菌胜肽市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 13 章：各国动物抗菌胜肽市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Esco Aster Pte. Ltd.
    • Biosynth Ltd
    • Vetoquinol SA
    • Phibro Animal Health Corporation
    • Dechra Pharmaceuticals PLC
    • Neogen Corporation
Product Code: MRR-4369010662C8

The Animal Antibacterial Peptide Market is projected to grow by USD 14.68 billion at a CAGR of 17.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.06 billion
Estimated Year [2025] USD 4.77 billion
Forecast Year [2032] USD 14.68 billion
CAGR (%) 17.40%

A strategic orientation to animal antibacterial peptides that frames scientific advances, regulatory shifts, stakeholder incentives, and practical adoption pathways for commercialization

The animal antibacterial peptide space has entered a period of intensified scientific and commercial attention as stakeholders respond to rising antimicrobial resistance and shifting regulatory expectations. Peptide-based antimicrobial strategies draw on diverse biological mechanisms that offer specificity, reduced propensity for resistance selection, and compatibility with integrated animal health programs. Advances in peptide synthesis, formulation, and targeted delivery have moved many concepts from academic proof-of-concept to translational development, prompting a broader set of commercial actors to evaluate peptides as viable alternatives or complements to traditional antibiotics. As a result, veterinarians, feed formulators, aquaculture operators, and biotechnology firms are reassessing therapeutic protocols, herd health economics, and product positioning with a clearer appreciation for the unique risk-return profile of peptide solutions.

Transition from laboratory innovation to commercial readiness requires navigating scientific validation, manufacturing complexity, and regulatory alignment. The introduction of robust analytical methods and scalable synthesis platforms has reduced technical barriers, while simultaneous progress in adjuvant and delivery technologies has enhanced in vivo efficacy and stability. These converging trends create a window of opportunity for organizations that can integrate multidisciplinary capabilities, engage early with regulatory bodies, and design pragmatic evidence-generation strategies. Moving forward, success will hinge on translating mechanistic advantages into demonstrable animal health outcomes, operational compatibility, and commercial value propositions that resonate across diverse end users.

An in-depth exploration of the pivotal shifts reshaping animal antibacterial peptide development driven by synthesis breakthroughs, diagnostics integration, and evolving regulatory acceptance

The landscape for animal antibacterial peptides is undergoing transformative shifts driven by technological, regulatory, and market catalysts that are redefining competitive dynamics. On the technological front, synthesis innovations and improved purification processes have materially reduced key technical bottlenecks, enabling manufacturers to produce peptides with higher fidelity and tailored physicochemical properties. Concurrently, precision diagnostics and pathogen surveillance are enabling more targeted therapeutic and prophylactic interventions, which strengthens the commercial case for products that offer narrow-spectrum or species-specific activity and minimize microbiome disruption.

Regulatory attitudes are also evolving: authorities are increasingly receptive to antimicrobial alternatives that demonstrate clear animal welfare benefits and environmental advantages, provided that rigorous safety and efficacy data accompany submissions. This regulatory momentum incentivizes manufacturers to pursue structured evidence-generation programs that incorporate field trials and comparative effectiveness endpoints. In parallel, end users such as feed manufacturers and aquaculture producers are seeking solutions that integrate seamlessly with existing production systems, creating demand for formulations that are stable in feed matrices or water and deliver predictable dosing. These cumulative shifts favor organizations that adopt a systems-based approach, aligning R&D, manufacturing, and commercialization to reduce friction between product attributes and operational realities.

A focused assessment of how cumulative United States tariff measures enacted in 2025 influence peptide input sourcing, contract manufacturing decisions, and supply chain resilience strategies

United States tariff actions in 2025 have amplified supply chain considerations for organizations involved in animal antibacterial peptide development and commercialization. Because peptide production often depends on specialized raw materials, reagents, and outsourced synthesis capacity, changes in tariff policy influence procurement strategies and the relative competitiveness of global versus domestic manufacturing. Firms that previously relied on low-cost international suppliers are reassessing total landed cost, lead times, and inventory policies to mitigate exposure to tariff volatility. As these strategic adjustments occur, some organizations are exploring nearshoring or establishing redundant supplier networks to preserve continuity of production and accelerate response to demand fluctuations.

At the operational level, tariff-related cost pressures can affect decisions about vertical integration, contract manufacturing partnerships, and the location of high-value activities such as analytical testing and final formulation. Companies with flexible supply chains that can adapt sourcing, qualify alternate reagents, and adjust batch scheduling will be better positioned to absorb tariff-driven dislocations without compromising timelines for development and commercialization. Additionally, heightened attention to procurement resilience is catalyzing investments in supplier qualification, strategic inventory buffering, and contractual safeguards that reduce the risk of price shocks. Taken together, the cumulative implications of tariff shifts in 2025 underscore the need for proactive supply chain redesign, scenario planning, and a more deliberate alignment of commercial cadence with manufacturing strategy.

Comprehensive segmentation-driven insight linking product type distinctions, application pathways, and end user configurations to evidence needs, formulation imperatives, and route-to-market choices

Understanding segmentation is essential to designing product portfolios and commercialization pathways that align with customer needs and technical feasibility. When products are viewed through the lens of product type, a primary distinction emerges between naturally derived peptides and synthetic peptides, with synthetic variants further differentiated by chain length into long chain, medium chain, and short chain classes that carry distinct stability, potency, and manufacturing implications. These product-level attributes influence formulation choices, route of administration, and cost structures, and they guide where firms should focus process development and analytical characterization efforts.

Viewing the landscape by application reveals divergent evidence requirements and adoption curves. Growth promotion approaches prioritize compatibility with feed systems and predictable performance under production conditions, whereas prophylactic uses, which include disease prevention strategies and vaccination adjuvants, demand strong safety profiles and clear benefits to herd immunity or disease incidence reduction. Therapeutic applications break down into infection treatment and skin disease treatment, each needing controlled clinical evaluation and dosing strategies that accommodate variability in species, age, and health status. The interplay between application demands and product attributes determines clinical trial design, regulatory pathway selection, and the nature of claims that can be pursued.

End user segmentation highlights operational and commercialization differences across aquaculture farms, feed manufacturers, research institutes, and veterinary clinics. Feed manufacturers must reconcile compatibility with aquafeed and livestock feed formats, focusing on processing stability and uniformity of dosing, while research institutes-which span academic institutes and biotech companies-drive early-stage discovery, mechanism elucidation, and translational studies. Veterinary clinics differentiate between large animal practice and small animal practice needs, which affects dosage forms, administration routes, and practitioner training requirements. These cross-cutting segmentation dimensions underscore that product development and commercialization cannot be one-size-fits-all; instead, they require tailored evidence packages, formulation strategies, and go-to-market models calibrated to each segment's technical constraints and decision drivers.

Regional commercialization and regulatory perspectives across the Americas, Europe Middle East and Africa, and Asia-Pacific that frame differential adoption paths and strategic priorities

Regional dynamics materially shape regulatory strategy, commercialization timing, and investment priorities across the animal antibacterial peptide domain. In the Americas, regulatory bodies and industry stakeholders emphasize antimicrobial stewardship and measurable reductions in antibiotic reliance, creating an environment where demonstrable animal health outcomes and economic justification influence purchasing decisions. This region's strong presence of multinational animal health companies and established contract manufacturing networks supports rapid scale-up for candidates that clear regulatory and clinical thresholds, but it also intensifies competition for veterinarian and producer attention.

In Europe, the Middle East and Africa, regulatory frameworks tend to be heterogeneous, with European jurisdictions often setting higher bars for safety and environmental impact while other countries within the broader region may prioritize access and affordability. Manufacturers seeking to operate across these territories must reconcile disparate approval pathways and data expectations, designing evidence generation strategies that anticipate the most rigorous regulatory requirements while remaining adaptable to local commercial conditions. The Asia-Pacific region presents a different set of dynamics: rapid growth in aquaculture and intensive livestock production creates significant demand for alternatives to conventional antibiotics, and regulatory modernization in several markets is opening pathways for novel interventions. However, the Asia-Pacific landscape also emphasizes cost competitiveness and supply chain proximity, so organizations must weigh pricing strategies and local manufacturing partnerships to gain traction. Across all regions, success depends on aligning scientific validation with pragmatic commercialization approaches that respect local regulatory nuance and customer economics.

Competitive and corporate innovation intelligence showing how incumbents, biotech innovators, and manufacturing specialists collaborate to advance peptide candidates and commercial readiness

The competitive environment for animal antibacterial peptides is characterized by a mix of established animal health companies, emerging biotech players, specialized peptide developers, and contract manufacturing organizations that together create a complex innovation ecosystem. Incumbent animal health firms bring strengths in regulatory navigation, distribution networks, and customer relationships, enabling them to integrate peptide-based products into existing portfolios where evidence supports clinical and economic value. Conversely, smaller biotechnology companies and academic spinouts frequently drive early-stage innovation, advancing novel sequences, delivery platforms, and mechanism-of-action insights that disrupt conventional approaches.

Strategic partnerships and licensing arrangements are common mechanisms to bridge capability gaps and accelerate commercialization. Larger companies may form research collaborations or co-development agreements with peptide specialists to access proprietary chemistries and scalable synthesis methods, while contract development and manufacturing organizations play a pivotal role in moving candidates from bench to GMP-compliant production. Investors and corporate development teams are increasingly attentive to companies that demonstrate clear translational pathways, reproducible manufacturing processes, and defensible intellectual property around peptide sequences and formulations. Competitive differentiation frequently rests on a combination of strong clinical evidence, manufacturing robustness, and the ability to deliver practical administration formats that fit into existing animal health workflows.

Actionable strategic recommendations for industry leaders to accelerate evidence generation, secure resilient supply chains, engage regulators early, and design end user-centric commercialization strategies

Industry leaders should execute a set of prioritized actions to accelerate responsible adoption and capture first-mover advantages while managing technical and commercial risk. First, invest in rigorous, outcome-focused evidence generation that pairs controlled clinical studies with real-world production trials; this dual approach demonstrates both efficacy under ideal conditions and practical benefits under operational realities. Second, develop modular manufacturing strategies that combine in-house capabilities for critical quality attributes with qualified contract partners to provide scale and redundancy, thereby mitigating supply risk and tariff-related disruptions.

Third, build regulatory engagement plans early in development to align study designs with the most stringent expected requirements and to accelerate approvals across multiple jurisdictions. Fourth, design product formats and distribution models that minimize disruption to end users' existing workflows by emphasizing feed-compatible formulations, easy-to-administer dosing systems, and clear guidance for practitioners. Fifth, pursue strategic alliances that couple proprietary peptide technologies with distribution channels and formulation expertise, enabling faster market entry and broader adoption. Implementing these recommendations requires cross-functional governance, disciplined portfolio prioritization, and a willingness to pilot innovative commercial models that reflect the nuanced needs of different end users.

Transparent research methodology combining structured stakeholder interviews, technical literature review, regulatory analysis, and cross-source validation to ensure robust and actionable conclusions

This analysis synthesizes primary and secondary research, technical literature review, and stakeholder engagement to construct an evidence-based perspective on animal antibacterial peptides. Primary inputs included structured interviews with veterinarians, feed formulators, contract manufacturers, and research scientists to ground technical claims in operational realities and to identify adoption barriers encountered in field settings. Secondary inputs encompassed peer-reviewed literature, regulatory guidance documents, and patent filings to map technological trajectories and intellectual property themes, while careful screening avoided relying on single-source commercial summaries.

Analytical methods combined qualitative thematic analysis of interview data with comparative evaluation of regulatory frameworks across jurisdictions to highlight cross-market differences in evidence expectations. Validation occurred through triangulation across data sources and follow-up consultations with subject-matter experts to test assumptions and refine interpretations. The approach emphasized transparency in assumptions, conservative interpretation of experimental results, and clear delineation between established facts and emerging hypotheses. Wherever possible, conclusions reflect consensus views rooted in reproducible methods and corroborating technical literature, ensuring that recommendations are actionable and aligned with current scientific and regulatory realities.

Concluding synthesis that integrates technical promise, commercialization realities, and strategic pathways to guide adoption and investment decisions in animal antibacterial peptides

In conclusion, animal antibacterial peptides represent a promising and pragmatic element of a broader strategy to reduce reliance on traditional antibiotics while improving animal health outcomes and production sustainability. Scientific advances in peptide design and delivery, coupled with evolving regulatory openness to alternatives, have improved the viability of peptide-based interventions. Nonetheless, successful commercialization depends on rigorous evidence of safety and efficacy, manufacturing scalability, and the ability to fit into existing operational models across diverse end users. Organizations that integrate cross-functional capabilities, pursue strategic partnerships, and adopt deliberate supply chain and regulatory strategies will be best positioned to translate scientific potential into commercial impact.

Looking ahead, the path to widespread adoption will be incremental and evidence-driven. Early successes will likely focus on niches where peptides clearly outperform alternatives, such as targeted prophylactic applications or skin disease treatments where topical or localized delivery reduces systemic exposure. Broader adoption will follow as cost-effective manufacturing and robust clinical datasets accumulate. For stakeholders that balance scientific rigor with pragmatic commercialization planning, peptides offer a credible route to meeting stewardship goals while preserving productivity and animal welfare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased adoption of plant-based feed supplements enriched with antibacterial peptide derivatives to improve livestock immunity
  • 5.2. Development of engineered antimicrobial peptides targeting specific zoonotic bacteria strains in poultry production systems
  • 5.3. Advances in peptide delivery technologies such as nanoencapsulation for targeted release in ruminant gastrointestinal tracts
  • 5.4. Regulatory incentives in North America and Europe driving research investments in non-antibiotic growth promotors for swine health
  • 5.5. Emergence of bacteriophage-peptide hybrid treatments for combating antibiotic-resistant infections in aquaculture species
  • 5.6. Strategic collaborations between biotech startups and veterinary pharmaceutical companies accelerating novel peptide therapeutics commercialization
  • 5.7. Integration of AI-driven peptide design platforms to optimize antibacterial efficacy and reduce development timelines in animal health

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Antibacterial Peptide Market, by Product Type

  • 8.1. Naturally Derived Peptide
  • 8.2. Synthetic Peptide
    • 8.2.1. Long Chain
    • 8.2.2. Medium Chain
    • 8.2.3. Short Chain

9. Animal Antibacterial Peptide Market, by Application

  • 9.1. Growth Promotion
  • 9.2. Prophylactic
    • 9.2.1. Disease Prevention
    • 9.2.2. Vaccination Adjuvant
  • 9.3. Therapeutic
    • 9.3.1. Infection Treatment
    • 9.3.2. Skin Disease Treatment

10. Animal Antibacterial Peptide Market, by End User

  • 10.1. Aquaculture Farms
  • 10.2. Feed Manufacturers
    • 10.2.1. Aquafeed
    • 10.2.2. Livestock Feed
  • 10.3. Research Institutes
    • 10.3.1. Academic Institute
    • 10.3.2. Biotech Company
  • 10.4. Veterinary Clinics
    • 10.4.1. Large Animal Practice
    • 10.4.2. Small Animal Practice

11. Animal Antibacterial Peptide Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Animal Antibacterial Peptide Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Animal Antibacterial Peptide Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Zoetis Inc.
    • 14.3.2. Elanco Animal Health Incorporated
    • 14.3.3. Merck & Co., Inc.
    • 14.3.4. Boehringer Ingelheim International GmbH
    • 14.3.5. Esco Aster Pte. Ltd.
    • 14.3.6. Biosynth Ltd
    • 14.3.7. Vetoquinol S.A.
    • 14.3.8. Phibro Animal Health Corporation
    • 14.3.9. Dechra Pharmaceuticals PLC
    • 14.3.10. Neogen Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. ANIMAL ANTIBACTERIAL PEPTIDE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. ANIMAL ANTIBACTERIAL PEPTIDE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL ANTIBACTERIAL PEPTIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLIN